You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Litigation Details for Biogen International GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)


✉ Email this page to a colleague

« Back to Dashboard


Biogen International GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)

Docket ⤷  Try a Trial Date Filed 2017-06-30
Court District Court, N.D. West Virginia Date Terminated 2020-06-22
Cause 35:271 Patent Infringement Assigned To Irene Patricia Murphy Keeley
Jury Demand None Referred To James P. Mazzone
Parties BIOGEN MA, INC.
Patents 10,029,015; 6,509,376; 6,926,907; 7,320,999; 7,619,001; 7,803,840; 8,013,002; 8,399,514; 8,759,393; 9,018,017; 9,024,096
Attorneys Sanya Sukduang
Firms Schrader Companion Duff & Law, PLLC
Link to Docket External link to docket
Small Molecule Drugs cited in Biogen International GMBH v. Mylan Pharmaceuticals Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , and ⤷  Try a Trial .
Biologic Drugs cited in Biogen International GMBH v. Mylan Pharmaceuticals Inc.

Details for Biogen International GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)

Date Filed Document No. Description Snippet Link To Document
2017-06-30 1 Complaint “the ‘999 patent”), 7,619,001 (“the ‘001 patent”), 7,803,840 (“the ‘840 patent”), 8,759,393 (“the ‘393…- 376 Patent, # 2 Exhibit B - 999 Patent, # 3 Exhibit C - 001 Patent, # 4 Exhibit D - 840 Patent, # 5 …is an action for patent infringement of U.S. Patent Nos. 6,509,376 (“the ‘376 patent”), 7,320,999 (“the…393 patent”) and 8,399,514 (“the ‘514 patent”) arising under the patent laws of the United States, Title…5 Exhibit E - 393 Patent, # 6 Exhibit F - 514 Patent, # 7 Civil Cover Sheet)(lmm) (Entered: 06/30/2017 External link to document
2018-10-12 142 Status Report infringement of U.S. Patent Nos. 6,509,376 (“the ’376 patent”), 7,320,999 (“the ’999 patent”), 7,619,001 … (“the ’001 patent”), 7,803,840 (“the ’840 patent”), 8,759,393 (“the ’393 patent”) and 8,399,514 … the patents-in-suit. The ’393 patent has expired. It is Mylan’s position that this patent should be…partes review (“IPR”) of Biogen’s ’514 patent. Biogen’s Patent Owner’s Preliminary Response is due on…for regulatory patent term extension (“PTE”) on the ’376, ’999, ’001, and ’840 patents. Under the relevant External link to document
2019-02-05 196 Stipulation and Order regarding U.S. Patent Nos. 6,509,376 (“the ’376 patent”), 7,320,999 (“the ’999 patent”), 7,803,840 (…affirmative defenses related to U.S. Patent Nos. 6,509,376; 7,320,999; 7,803,840; and 8,759,393. The parties…regarding the ’376 patent, the ’999 patent, the ’840 patent, and the ’393 patent; (iii) Defendants…regarding the ’376 patent, the ’999 patent, the ’840 patent, and the ’393 patent; and (iv…counterclaims regarding ’376 patent, the ’999 patent, the ’840 patent, and the ’393 patent. It is further External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.